drugset / Trial / NCT00989703

GLPG0259 Multiple Ascending Dose and Methotrexate Drug-drug Interaction (DDI) in Healthy Subjects

NCT00989703

Phase 1 Completed 24 enrolled Lakefront Biotherapeutics NV
RandomizedParallel-groupQuadruple-blind

Summary

The purpose of the study is to evaluate the safety and tolerability of multiple increasing oral doses of GLPG0259 compared to placebo. Also, pharmacokinetics (PK) and pharmacodynamics (PD) of GLPG0259 after multiple increasing oral doses, and potential drug-drug interaction with single dose methotrexate will be assessed.

Timeline

Start
2009-09
Primary completion
2009-11
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject GLPG0259 Small molecule 25 mg Oral
Subject GLPG0259 Small molecule 50 mg Oral
Subject GLPG0259 Small molecule 75 mg Oral
Subject Methotrexate Small molecule 7.5 mg

Indications

No indication recorded.